Expression of a "self-"antigen by human tumor cells enhances tumor antigen-specific CD4(+) T-cell function.

Expression of a "self-"antigen by human tumor cells enhances tumor antigen-specific CD4(+) T-cell function. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Expression of a "self-"antigen by human tumor cells enhances tumor antigen-specific CD4(+) T-cell function. Abstract Text:

Christopher E Touloukian,Wolfgang W Leitner,Paul F Robbins,Yong F Li,Xiaoqiang Kang,Rejean Lapointe,Patrick Hwu,Steven A Rosenberg,Nicholas P Restifo,

CD4(+) T cells can recognize "self" tumor antigens, but the impact of tumor cell expression of self-antigens on CD4(+) T-cell function in humans is unknown. Here, we identify a new epitope (ISPNSVFSQWRVVCDSLEDYD) derived from tyrosinase-related protein-1 (TRP-1) using a predictive algorithm and mice transgenic for a chimeric HLA-DRB1*0401 molecule. We then compared the functions of TRP-1-epitope-specific, CD4(+) T-cell responses in normal healthy individuals to those found in patients with metastatic malignant melanoma. Surprisingly, we found that tumor-bearing patients had significantly higher levels of TRP-1-specific, CD4(+) T-cell function than healthy volunteers as measured ex vivo. Thus, the net effect of "self" antigen expression by tumor cells was the enhancement of tumor antigen-specific CD4(+) T-cell function, rather than immunosuppression. These findings indicate that antigens expressed by malignant melanoma cells can partially activate CD4(+) T lymphocytes.

Expression of a "self-"antigen by human tumor cells enhances tumor antigen-specific CD4(+) T-cell function. Publishing Authors By Initials

CE Touloukian,WW Leitner,PF Robbins,YF Li,X Kang,R Lapointe,P Hwu,SA Rosenberg,NP Restifo,

For similar proteins research abstracts see: proteins research

PUBMED ID PMID:

MEDLINE DATE:

Expression of a "self-"antigen by human tumor cells enhances tumor antigen-specific CD4(+) T-cell function. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Cancer research

VOLUME: 62

Page Numbers: 5144-7

Journal Abbreviation: Cancer Res.

ISSN: 0008-5472

DAY: 15

MONTH: Sep

YEAR: 2002

Expression of a "self-"antigen by human tumor cells enhances tumor antigen-specific CD4(+) T-cell function. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 2984705

Expression of a "self-"antigen by human tumor cells enhances tumor antigen-specific CD4(+) T-cell function. Keywords Mesh Terms:

KEYWORDS: Proteins

MESH TERMS: immunology

Chemical & Substance for Abstract: Expression of a "self-"antigen by human tumor cells enhances tumor antigen-specific CD4(+) T-cell function. Information

Substance Name: tyrosinase-related protein

Registry Number: EC 1.14.18.-

Grant and Affiliation Information for Expression of a "self-"antigen by human tumor cells enhances tumor antigen-specific CD4(+) T-cell function.

AFFILIATION: National Cancer Institute, NIH, Building 10, Room 2B42, Bethesda, MD 20892, USA.

Country: United States

AGENCY: United States NCI

GRANT: Z01 BC010763-01

ACRONYM: BC

MEDLINETA: Cancer Res

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Expression of a "self-"antigen by human tumor cells enhances tumor antigen-specific CD4+ T-cell function Related Publications

• Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen.
• Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways.
• Autoimmunity and the immunotherapy of cancer: targeting the "self" to destroy the "other".
• Building better vaccines: how apoptotic cell death can induce inflammation and activate innate and adaptive immunity.
• CD8+ T-cell memory in tumor immunology and immunotherapy.
• Cancer vaccines: progress reveals new complexities.
• Countering the 'counterattack' hypothesis.
• Creating therapeutic cancer vaccines: notes from the battlefield.
• Cutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen.
• Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases.
• DNA and RNA-based vaccines: principles, progress and prospects.
• Do CD4+ CD25+ immunoregulatory T cells hinder tumor immunotherapy?
• Enhancement of tumor-specific immune response with plasmid DNA replicon vectors.
• Expression of a "self-"antigen by human tumor cells enhances tumor antigen-specific CD4(+) T-cell function.
• Hierarchy, tolerance, and dominance in the antitumor T-cell response.
• IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression.
• IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases.
• Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice.
• Insertion signal sequence fused to minimal peptides elicits specific CD8+ T-cell responses and prolongs survival of thymoma-bearing mice.
• Minimal determinant expressed by a recombinant vaccinia virus elicits therapeutic antitumor cytolytic T lymphocyte responses.
• Mining the melanosome for tumor vaccine targets: P.polypeptide is a novel tumor-associated antigen.
• Natural selection of tumor variants in the generation of "tumor escape" phenotypes.
• NeuronMetrics: software for semi-automated processing of cultured neuron images.
• Normal tissue depresses while tumor tissue enhances human T cell responses in vivo to a novel self/tumor melanoma antigen, OA1.
• Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape.
• Synthetic oligonucleotide expressed by a recombinant vaccinia virus elicits therapeutic CTL.
• The future of interleukin-2: enhancing therapeutic anticancer vaccines.
• Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen.
• Toll-like receptors in tumor immunotherapy.
• Vaccines to die for.